Slow-release eye drops and preparation method thereof
A technology for sustained-release eye drops and sustained-release drugs, which is applied in the directions of pharmaceutical formulations, medical preparations containing inactive ingredients, and medical preparations containing active ingredients, and achieves the effects of simple preparation method, convenient use and low cost
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0053] A sustained-release eye drop comprising sustained-release drug 1 and dispersion liquid 2. Such as Figure 3a As shown, the sustained-release drug 1 comprises an ophthalmic drug 10 and a sustained-release carrier. The slow-release carrier includes: nanoparticles 21 and a surface function modification layer 22 . Wherein, the nanoparticle 21 is selected metal hydroxide nanoparticle, and its SEM picture is as follows Figure 3b Shown; the biological material constituting the surface function modification layer 22 is sodium hyaluronate. The ophthalmic drug 10 loaded on the sustained-release carrier is a small-molecule integrin antagonist, and its loading amount in the sustained-release carrier accounts for 2% of the total mass of the sustained-release drug 1 .
[0054] The preparation method of sustained-release eye drops of the present invention comprises:
[0055] Step 1, using a hydrothermal method to synthesize metal hydroxide nanoparticles, specifically including: p...
Embodiment 2
[0060] A kind of sustained-release eye drops, wherein, described nanoparticle 21 selects montmorillonite nanoparticle, and its SEM figure is as follows Figure 4a As shown; due to the serious agglomeration of montmorillonite, the outline of nanoparticles in the SEM image is not very clear. The biological material constituting the surface functional modification layer 22 is cationic gelatin; the structural representation of montmorillonite nanoparticles, surface functional modification layer and drug loading is as follows: Figure 4b shown. The ophthalmic drug 10 loaded on the sustained-release carrier is an anti-inflammatory drug dexamethasone;
[0061] In the preparation process, first synthesize montmorillonite nanoparticles, then use cationic gelatin to modify montmorillonite nanoparticles by physical adsorption, and then load dexamethasone (dexamethasone) in the surface-modified montmorillonite nanoparticles, The drug-loaded solid powder is obtained by freeze-drying; fin...
Embodiment 3
[0066] A sustained-release eye drop, the nanoparticles 21 are metal hydroxide nanoparticles; the biological material forming the surface function modification layer is sodium alginate; the ophthalmic drug loaded by the sustained-release carrier is levofloxacin (levofloxacin) ; The loading amount of the ophthalmic drug in the sustained-release carrier accounts for 1.5% of the total mass of the sustained-release drug.
[0067] In the preparation process, metal hydroxide nanoparticles were first prepared by hydrothermal synthesis, and then sodium alginate was used to modify metal hydroxide nanoparticles by physical adsorption, and then levofloxacin was loaded on the surface-modified metal Hydroxide nanoparticles are freeze-dried to obtain drug-loaded solid powder; finally, the solid sustained-release drug powder is sterilized, and together with the dispersion, are packaged in dry-wet separation eye drop bottles.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


